Payment overview · 2025
General Payments
$39.28
2 reported records · 1 companies
Healthcare provider profile · identity verified
Victor Manuel Reyes, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CAGUAS, PR · NPI 1104803113
Verified facts
What the public records show
CMS Open Payments records show Victor Manuel Reyes, M.D. received $39.28 in general payments during 2025 across 2 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.28 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $39.28 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
157 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Famotidine | Famotidine | 1674 | 336 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1141 | 362 |
| Losartan Potassium | Losartan Potassium | 821 | 245 |
| Gabapentin | Gabapentin | 729 | 165 |
| Synthroid | Levothyroxine Sodium | 707 | 135 |
| Pantoprazole Sodium | Pantoprazole Sodium | 691 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 663 | 206 |
| Metformin Hcl | Metformin Hcl | 621 | 172 |
| Simvastatin | Simvastatin | 612 | 191 |
| Levothyroxine Sodium | Levothyroxine Sodium | 526 | 122 |
| Omeprazole | Omeprazole | 525 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 511 | 163 |
| Metoprolol Succinate | Metoprolol Succinate | 510 | 155 |
| Alendronate Sodium | Alendronate Sodium | 503 | 106 |
| Fluticasone Propionate | Fluticasone Propionate | 324 | 132 |
| Montelukast Sodium | Montelukast Sodium | 320 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 283 | 78 |
| Clopidogrel | Clopidogrel Bisulfate | 255 | 77 |
| Lisinopril | Lisinopril | 249 | 79 |
| Januvia | Sitagliptin Phosphate | 245 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 239 | 76 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 227 | 72 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 215 | 39 |
| Sertraline Hcl | Sertraline Hcl | 203 | 71 |
| Irbesartan | Irbesartan | 183 | 55 |
| Ezetimibe | Ezetimibe | 182 | 61 |
| Fenofibrate | Fenofibrate | 173 | 49 |
| Xarelto | Rivaroxaban | 171 | 28 |
| Eliquis | Apixaban | 164 | 24 |
| Candesartan Cilexetil | Candesartan Cilexetil | 163 | 42 |
| Farxiga | Dapagliflozin Propanediol | 157 | 29 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 149 | 80 |
| Pentoxifylline | Pentoxifylline | 146 | 26 |
| Glimepiride | Glimepiride | 134 | 41 |
| Carvedilol | Carvedilol | 133 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 127 | 88 |
| Glipizide | Glipizide | 126 | 30 |
| Jardiance | Empagliflozin | 116 | 21 |
| Enalapril Maleate | Enalapril Maleate | 114 | 34 |
| Nifedipine Er | Nifedipine | 106 | 30 |
| Meloxicam | Meloxicam | 105 | 77 |
| Tradjenta | Linagliptin | 104 | 16 |
| Cilostazol | Cilostazol | 103 | 25 |
| Finasteride | Finasteride | 103 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 101 | 56 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 100 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 93 | 29 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 91 | 26 |
| Glipizide Er | Glipizide | 91 | 23 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 91 | 11 |
| Pregabalin | Pregabalin | 89 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 29 |
| Latanoprost | Latanoprost | 85 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 81 | 15 |
| Atenolol | Atenolol | 76 | 23 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 76 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 21 |
| Warfarin Sodium | Warfarin Sodium | 72 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 22 |
| Furosemide | Furosemide | 68 | 23 |
| Valsartan | Valsartan | 64 | 16 |
| Memantine Hcl | Memantine Hcl | 63 | 23 |
| Ibandronate Sodium | Ibandronate Sodium | 62 | 18 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 62 | 22 |
| Trazodone Hcl | Trazodone Hcl | 61 | 17 |
| Lansoprazole | Lansoprazole | 60 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 13 |
| Allopurinol | Allopurinol | 58 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 18 |
| Terazosin Hcl | Terazosin Hcl | 56 | 15 |
| Donepezil Hcl | Donepezil Hcl | 52 | 20 |
| Humalog | Insulin Lispro | 52 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 47 |
| Azithromycin | Azithromycin | 48 | 47 |
| Diclofenac Potassium | Diclofenac Potassium | 48 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 15 |
| Telmisartan | Telmisartan | 48 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 17 |
| Prednisone | Prednisone | 46 | 35 |
| Metformin Hcl Er | Metformin Hcl | 44 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 41 | 11 |
| Bupropion Xl | Bupropion Hcl | 41 | 13 |
| Spironolactone | Spironolactone | 41 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 39 | 11 |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 38 | 27 |
| Azelastine Hcl | Azelastine Hcl | 37 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 37 | 11 |
| Insulin Lispro | Insulin Lispro | 35 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Brilinta | Ticagrelor | 34 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Rivastigmine | Rivastigmine | 31 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 29 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 27 | 11 |
| Ciclopirox | Ciclopirox | 27 | 22 |
| Ozempic | Semaglutide | 27 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 26 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 13 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 19 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Insulin Glargine | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $39.28 · 2 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error